Syros Pharmaceuticals Stock Return On Equity
| SYRSDelisted Stock | USD 0.06 0.01 10.35% |
Fundamental analysis of Syros Pharmaceuticals allows traders to better anticipate movements in Syros Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Syros |
Syros Pharmaceuticals Company Return On Equity Analysis
Syros Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Syros Pharmaceuticals Return On Equity | -7.77 |
Most of Syros Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Syros Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Syros Pharmaceuticals has a Return On Equity of -7.7696. This is 67.59% lower than that of the Biotechnology sector and 78.69% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Syros Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Syros Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Syros Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syros Pharmaceuticals by comparing valuation metrics of similar companies.Syros Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Syros Fundamentals
| Return On Equity | -7.77 | ||||
| Return On Asset | -0.6 | ||||
| Operating Margin | (288.92) % | ||||
| Current Valuation | 3.6 M | ||||
| Shares Outstanding | 26.83 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 33.97 % | ||||
| Number Of Shares Shorted | 913.09 K | ||||
| Price To Earning | (7.92) X | ||||
| Price To Book | 10.65 X | ||||
| Price To Sales | 13.91 X | ||||
| Revenue | 9.94 M | ||||
| Gross Profit | (88.25 M) | ||||
| EBITDA | (157.19 M) | ||||
| Net Income | (164.57 M) | ||||
| Cash And Equivalents | 244.48 M | ||||
| Cash Per Share | 12.09 X | ||||
| Total Debt | 62.08 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 6.57 X | ||||
| Book Value Per Share | (0.41) X | ||||
| Cash Flow From Operations | (109.71 M) | ||||
| Short Ratio | 0.80 X | ||||
| Earnings Per Share | (1.80) X | ||||
| Target Price | 8.75 | ||||
| Number Of Employees | 68 | ||||
| Beta | 1.31 | ||||
| Market Capitalization | 5.37 M | ||||
| Total Asset | 168.17 M | ||||
| Retained Earnings | (722.81 M) | ||||
| Working Capital | 108.3 M | ||||
| Current Asset | 85.51 M | ||||
| Current Liabilities | 9.57 M | ||||
| Net Asset | 168.17 M |
About Syros Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Syros Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syros Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syros Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Syros Pink Sheet
If you are still planning to invest in Syros Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Syros Pharmaceuticals' history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |